Transconjunctival versus Transcutaneous Injection of Botulinum Toxin into the Lacrimal Gland to Reduce Lacrimal Production: A Randomized Controlled Trial

• Published in: Toxins Vol. 13; no. 2; p. 77
• Main Authors: Lee, Andrew G, Lee, Shin-Hyo, Jang, Minsu, Lee, Sang Jae, Shin, Hyun Jin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.01.2021; MDPI
• Subjects: Anesthesia; Botulinum toxin; Botulinum toxin type A; delivery route; Diplopia; epiphora; Injection; lacrimal gland; Lacrimal gland and Nasolacrimal duct; lacrimal obstruction; Meniscus; Patient satisfaction; Quality of life; Silicones; Success; Toxins; botulinum toxin; epiphora; lacrimal gland; delivery route; lacrimal obstruction
• DOI: 10.3390/TOXINS13020077
• ISSN: 2072-6651

The purpose of this study was to determine and compare the effects between injecting botulinum toxin A (BTX-A) transconjunctivally into the palpebral lobe and transcutaneously into the orbital lobe of the lacrimal gland in patients with epiphora due to lacrimal outflow obstruction. This randomized controlled study included 53 eyes of 31 patients with unilateral or bilateral epiphora. Patients were randomly allocated to receive an injection of BTX-A (3 units) either transconjunctivally ( = 15, 25 eyes) or transcutaneously ( = 16, 28 eyes). For objective assessments, the tear meniscus height and Schirmer's I test with topical anesthesia were measured at baseline and after 2, 6, 12, and 24 weeks of follow-up. Subjective evaluations were performed using the Munk score. After BTX-A injection, patients in both groups experienced significant objective and subjective reductions in tearing at all follow-up times compared to pre-injection (success rate 86.8%), and the effect lasted for a mean duration of 5.63 months. The two delivery routes showed similar clinical effectiveness for a single injected dose of BTX-A. In conclusion, injecting BTX-A via either a transconjunctival or transcutaneous route helps to reduce normal tear production and results in significant improvements in the symptoms in patients with epiphora.